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Research
Neonatal factors can cause latent functional
changes that increase susceptibility to disease
and/or dysfunction later in life. This hypothe-
sis of the “developmental origins of adult dis-
ease” was originally derived from studies that
identiﬁed stroke as one of several cardiovascu-
lar diseases associated with low birth weight
(McMillen and Robinson 2005; Morley
2006). Subsequently, brief separations of
infant mice from their mothers were demon-
strated to increase their sensitivity to cerebral
ischemic injury as adults, an effect mediated
by functional changes in the hypothalamic–
pituitary axis and inflammatory response
(Craft et al. 2006). Recent evidence linking
developmental exposure to environmental
contaminants of concern to neurodegenerative
diseases (Barlow et al. 2007; Bolin et al. 2006;
Zawia and Basha 2005) suggests a third cate-
gory of neonatal factors that inﬂuences suscep-
tibility of the adult brain to injury, but
whether these factors inﬂuence adult sensitiv-
ity to stroke has not been investigated. 
Polychlorinated biphenyls (PCBs) are
organic compounds that were used mostly as
coolants and lubricants from the 1930s until
1977, when they were banned. Despite the
ban, PCBs persist in environmental samples,
and high residue levels are still detected in
foods, particularly ﬁsh (Kostyniak et al. 2005;
Stewart et al. 1999), and in human tissue sam-
ples (Chu et al. 2003; Covaci et al. 2002;
DeCaprio et al. 2005; Jursa et al. 2006).
Epidemiologic and laboratory evidence suggests
that PCBs increase the incidence of risk factors
for stroke such as diabetes (Everett et al. 2007;
Longnecker and Daniels 2001; Vasiliu et al.
2006) and vascular disease (Carpenter 2006;
Hennig et al. 2005); also, living near hazardous
waste sites contaminated with PCBs was
recently linked to increased stroke incidence
(Shcherbatykh et al. 2005). However, these
studies did not address whether PCBs inﬂuence
stroke outcome (the extent of damage occur-
ring after a stroke) nor did they consider the
contribution of developmental exposure to
PCBs in determining adult susceptibility to
cerebral ischemia. The developing nervous sys-
tem is particularly sensitive to PCBs (Carpenter
2006; Schantz et al. 2003), and in experimental
models, exposure of the developing brain to
PCBs alters gene expression (Basha et al. 2006)
and seizure susceptibility (Pessah IN, personal
communication) in the adult brain. 
Factors known to influence stroke out-
come include estrogen (Hurn et al. 2005) and
preconditioning, a well-described phenome-
non in which exposure to a mild ischemic or
noxious stress up-regulates endogenous anti-
oxidant and anti-inﬂammatory mechanisms to
protect the brain against subsequent more
severe ischemic injury (Koerner and Alkayed
2007). Although mechanisms of precondi-
tioning are not completely understood,
de novo gene expression in the brain is clearly
required. Bcl2 (B-cell leukemia/lymphoma 2)
and Cyp2C11 (cytochrome P450 2C11) are
two genes whose up-regulation has been func-
tionally implicated in preconditioning
(Koerner and Alkayed 2007). Bcl2 protects
neurons against ischemic injury via its anti-
apoptotic activity (Kitagawa 2007; Mattson
2007), and CYP2C11 metabolizes arachi-
donic acid to expoxyeicosatrienoic acids,
which are thought to protect against cerebral
ischemia via vasodilatory, anti-inflammatory
and antioxidant activities (Koerner and
Alkayed 2007). Developmental PCB exposure
modulates systemic (Meerts et al. 2004) and
brain (Colciago et al. 2006) levels of estrogen,
increases Bcl2 expression in adult testes (Hsu
et al. 2007), and increases expression and
activity of hepatic Cyp2C11 (Chen et al.
1992; Kramer et al. 1999). These observations
suggest that developmental exposure to PCBs
may alter stroke outcome. We tested this
hypothesis using a well-established animal
model of focal cerebral ischemia to quantify
brain infarction in rats exposed throughout
gestation and lactation to the commercial
PCB mixture Aroclor 1254 (A1254).
Although our ﬁndings are paradoxical in that
developmental PCB exposure was observed to
protect against stroke damage, they are of
public health signiﬁcance in that they identify
developmental exposures to environmental
contaminants as potentially signiﬁcant deter-
minants of adult susceptibility to cerebral
ischemia. 
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BACKGROUND: The “developmental origins of adult disease” hypothesis was originally derived from
evidence linking low birth weight to cardiovascular diseases including stroke. Subsequently, it has
been expanded to include developmental exposures to environmental contaminants as risk factors
for adult onset disease. 
OBJECTIVE: Our goal in this study was to test the hypothesis that developmental exposure to poly-
chlorinated biphenyls (PCBs) alters stroke outcome in adults. 
METHODS: We exposed rats to the PCB mixture Aroclor 1254 (A1254) at 0.1 or 1 mg/kg/day in
the maternal diet throughout gestation and lactation. Focal cerebral ischemia was induced at
6–8 weeks of age via middle cerebral artery occlusion, and infarct size was measured in the cerebral
cortex and striatum at 22 hr of reperfusion. PCB congeners were quantiﬁed in brain tissue by gas
chromatography with microelectron capture detection, and cortical and striatal expression of Bcl2
and Cyp2C11 were quantiﬁed by quantitative reverse transcriptase-polymerase chain reaction.
RESULTS: Developmental exposure to A1254 signiﬁcantly decreased striatal infarct in females and
males at 0.1 and 1 mg/kg/day, respectively. Predominantly ortho-substituted PCB congeners were
detected above background levels in brains of adult females and males exposed to A1254 at 1 but
not 0.1 mg/kg/day. Effects of developmental A1254 exposure on Bcl2 and Cyp2C11 expression did
not correlate with effects on infarct volume. 
CONCLUSION: Our data provide proof of principle that developmental exposures to environmental
contaminants inﬂuence the response of the adult brain to ischemic injury and thus represent poten-
tially important determinants of stroke susceptibility.
KEY WORDS: Aroclor 1254, cerebral ischemia, developmental origins of adult disease, polychlori-
nated biphenyls, stroke. Environ Health Perspect 116:474–480 (2008). doi:10.1289/ehp.10828
available via http://dx.doi.org/ [Online 14 January 2008]Materials and Methods
Animals and PCB exposures. All animals used
in these studies were treated humanely and
with regard for alleviation of suffering, and all
protocols involving animals were approved by
the Oregon Health & Science University
Institutional Animal Care and Use Committee
prior to the initiation of experimentation.
Adult male and female Wistar rats were pur-
chased from Charles River Laboratories
(Hollister, CA) and housed individually,
except during breeding, in standard plastic
cages with Alpha-Dri bedding (Shepherd
Specialty Papers, Watertown, TN) in a tem-
perature-controlled room (22 ± 2°C) on a
12-hr reverse light–dark cycle. Food and water
were provided ad libitum. Dams used in the
study delivered a litter of 10–15 pups (n = 5–7
dams per treatment group). On postnatal day
(PND) 2, litters were culled to 10 pups. Pups
were weaned on PND21. 
Dams were dosed with A1254 (lot
124-191; purity > 99%; AccuStandard, New
Haven, CT) at 0.1 or 1 mg/kg/day beginning
2 weeks prior to breeding and continuing
until PND21. A1254 diluted in HPLC-grade
methanol was pipetted onto Keebler Golden
Vanilla Wafers (Kellogg Company, Battle
Creek, MI), which were fed to dams daily
throughout the exposure period. Controls
received wafers dosed with an equal volume
of vehicle. Dams were observed to ensure the
entire wafer was consumed (typically within
5 min), and pups were not allowed access to
the wafers. 
Experimental stroke in rat. When off-
spring reached 225–275 g body weight
(6–8 weeks for males; 8–10 weeks for females),
we induced transient focal cerebral ischemia by
middle cerebral artery occlusion (MCAO)
using the intraluminal ﬁlament technique with
halothane anesthesia inO2-enriched air, as pre-
viously described (Rusa et al. 1999). Tissue
perfusion over the ipsilateral parietalcortex was
monitored using a laser-Doppler probe (Moor
Instruments Ltd., Oxford, UK) placed 6 mm
lateral and 2 mm posterior to bregma. Vascular
occlusion was maintained for 2 hr, then the
occluding filament was withdrawn and the
brain reperfused for 22 hr. This typically
results in a core infarct limited to the ipsilateral
cortex and striatum. After 22 hr of reperfusion,
brains were collected, immediately sectioned
(seven 2-mm-thick coronal sections per brain)
and stained with 2,3,5-triphenyltetrazolium
chloride (TTC), which is a commonly used
and highly reproducible method for determin-
ing infarct volume in the brain (Dettmers et al.
1994; Hatﬁeld et al. 1991; Okuno et al. 2001;
Tureyen et al. 2004). In viable tissue, the TTC
salt accepts a proton from succinate dehydro-
genase in the inner mitochondrial membrane,
which leaves the succinate dehydrogenase in a
reduced state. Reduced succinate dehydroge-
nase forms a red insoluble product, formazan,
causing brain tissue to develop a red hue. In
contrast, infarcted areas of brain tissue cannot
reduce succinate dehydrogenase and therefore
remain pale. After TTC staining, the rostral
and caudal sides of each coronal section were
digitally photographed (Figure 1) and the
infarct area quantified using MCID image
analysis software (InterFocus Imaging Ltd.,
Cambridge, UK). We integrated rostral and
caudal infarct areas across all seven sections
from each brain to calculate the infarct volume.
To normalize for poststroke edema, infarct
volume in the hemisphere, cortex, and stria-
tum is expressed as a percentage of the corre-
sponding contralateral structures, which were
identified using defined anatomical markers
(Paxinos and Watson 1986). 
Hepatic cytochrome P450 activity. We
analyzed 7-ethyoxyresorufin O-deethylase
(EROD) and 7-pentoxyresoruﬁn O-depenty-
lase (PROD) activities in hepatic microsomes
isolated from rats used in MCAO studies
according to the method of Lubet (1990), as
modified by Kennedy and Jones (1994) and
Kono et al. (1999). We measured resorufin
formation using a Fusion Universal Microplate
Analyzer (Packard Instruments, Meriden, CT)
with an excitation filter of 544 nm and an
emission filter of 590 nm. Enzyme activities
were normalized to protein concentration as
determined using the BCA Protein Assay
(Pierce, Rockford, IL). 
Congener-specific analysis of PCBs in
brain tissue. Whole brains harvested from
PND62 rats were stored at –80°C and thawed
immediately before extraction, cleanup, and
fractionation using gel permeation chromatog-
raphy as previously described (Sethajintanin
et al. 2004). We used tetrachloro-m-xylene
(TCMX) in hexanes in all samples as the
internal surrogate standard. Additional fortiﬁ-
cation samples spiked with a 20-ng/g PCB
mixture were included in all batches. Speciﬁc
PCB congeners were determined using gas
chromatography with microelectron capture
detection (Agilent 6890N Network GC sys-
tem; Agilent Technologies, Santa Clara, CA)
as previously described (Sethajintanin and
Anderson 2006). To minimize batch-to-batch
bias, samples from any designated group were
typically analyzed in three different batches.
Reagent and extraction blanks were included
in every batch. Quality control samples repre-
sented 30–40% of a sample set and were
processed and analyzed exactly the same as
samples. The method detection limits were
determined as 3 times the heights of coinci-
dent peaks observed for each compound in the
control rat tissue. None of the target analytes
were identified in the reagent or extraction
blanks. Recovery of the internal surrogate
TCMX ranged from 45 to 86%. The average
percent recovery of fortified samples was
59.9–97.2% for target PCB congeners. 
Quantitative reverse transcriptase-poly-
merase chain reaction (qRT-PCR). PND7 and
PND50 rats were euthanized and the brains
excised; cortices and caudate putamen were
rapidly dissected, snap frozen, and stored at
–80°C. Total RNA was isolated using RNeasy
(QIAGEN, Valencia, CA); RNA amount and
quality were determined by spectrophotome-
try and gel electrophoresis, respectively; and,
cDNA was reverse transcribed from 500 ng
total RNA (High Capacity cDNA Archive
Kit; Applied Biosystems, Foster City, CA).
Primers and probes specific for rat B-cell
leukemia/lymphoma 2 (Bcl2, GenBank acces-
sion no. NM 016993; GenBank 2007) and
18S RNA were as previously described (Cheng
et al. 2007). Primers and probes speciﬁc for rat
cytochrome P450 2C11 (Cyp2C11, GenBank
accession no. X79081) were designed using
Primer Express (Applied Biosystems) and pur-
chased from Integrated DNA Technologies
(Coralville, IA): forward and reverse primer
sequences were 5´-CGCCGTTTCTCCAT-
CATGA-3´ and 5´-TCTTGAATACGGTC-
CTCAATGGT-3´, respectively; probe
sequence was 5´-/56-FAM/CTCTTGCC-
CATCCCAAAAGTCCTCAGG/36-
TAMsp/-3´. We determined the amount of
target gene in experimental samples by linear
regression analyses using a standard curve gen-
erated for each target gene. Expression levels
of target genes were normalized against
endogenous 18S RNA levels. 
Plasma levels of sex steroids. After 22 hr of
reperfusion, each animal was deeply anes-
thetized with halothane, and blood samples
were obtained by cardiac puncture for meas-
urement of plasma 17β-estradiol and testos-
terone by radioimmunoassay as previously
described by Alkayed et al. (2000). 
Statistical analyses. We analyzed infarct
volume by two-way analysis of variance
(ANOVA) for factors of region and dose in
each sex, and all other data were analyzed by
ANOVA for treatment effects. If significant
effects were identified (p < 0.05), post hoc
analyses were performed using the Newman-
Keuls multiple comparison test. 
PCBs alter stroke outcome
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Figure 1. Method for identifying infarct area illus-
trated in a representative digital image of a TTC-
stained coronal slice. Tissue infarction appears as
the absence of TTC staining (left), and the contra-
lateral cortex and striatum (right) were identified
using defined anatomical markers (Paxinos and
Watson 1986). 
Ischemia Contralateral
Total cortex
Total
striatum
Infarcted
cortex
Infarcted
striatumDziennis et al.
476 VOLUME 116 | NUMBER 4 | April 2008 • Environmental Health Perspectives
Results
Effects of A1254 treatment on maternal and
fetal toxicity. Exposure of dams to A1254 at
0.1 or 1.0 mg/kg/day did not alter maternal
weight gain during gestation, maternal body
weight during lactation, length of gestation,
litter size, or sex ratio relative to vehicle
controls (Figure 2A–D). Body weight of
the offspring was similarly unaffected by
developmental PCB exposure, with the excep-
tion of a transient decrease at PND45 in
females in the 0.1-mg/kg/day treatment group
(Figure 2E,F). 
Effect of developmental PCB exposure on
infarct volume after ischemic stroke. To test the
hypothesis that developmental PCB exposure
influences adult sensitivity to ischemic brain
injury, we performed transient MCAO in adult
rats exposed throughout gestation and lactation
to A1254 in the maternal diet. The survival rate
was 100% in all treatment groups. Arterial
blood pressure and gases, body temperature,
and laser Doppler perfusion values were moni-
tored throughout surgery, MCAO, and early
reperfusion. Physiologic values obtained from
the midpoint of MCAO were generally compa-
rable between treatment groups (Table 1).
While mean arterial blood pressure and blood
glucose were signiﬁcantly decreased in a subset
of A1254 dose groups, these lower values were
still well within the normal physiologic range
for these parameters. However, relative to vehi-
cle controls (Figure 3A), infarct volume was sig-
niﬁcantly decreased in both females and males
exposed developmentally to A1254, although
in females this effect was observed only in the
lower A1254 dose group (Figure 3B,C) and in
males only in the higher A1254 dose group
(Figure 3D). Although similar trends were
noted in the cortex and total hemisphere, sig-
niﬁcant treatment-related effects were limited
to the striatum.
Effects of developmental A1254 exposure on
hepatic CYP activity and adult brain PCB
levels. A question raised by the stroke studies
was why females were more sensitive to the
neuroprotective effects of developmental A1254
exposure than males. One possible mechanism
is differences in PCB metabolism between the
sexes. As an indirect test of this hypothesis, we
measured CYP activities in hepatic microsomes
from animals receiving MCAO and quantiﬁed
PCB brain levels in comparably aged litter-
mates. In vehicle controls, EROD activity was
similar between females and males; however,
developmental A1254 exposure significantly
increased EROD activity among females in the
high-dose group but not among males in either
A1254 dose group (Figure 4A). PROD activity
was signiﬁcantly higher among vehicle control
males than among females, and developmental
exposure to A1254 increased PROD activity in
both females and males (Figure 4B). In females,
this effect was observed only in the high-dose
group, whereas in males, this effect was
observed in both A1254 dose groups. 
Of the 32 congeners chosen for analysis
based on their toxicity, presence in A1254,
abundance in environmental samples, and ana-
lytical capability, 31 were below the detection
limit in brains of vehicle controls (Table 2); the
one congener that was detected (PCB-153) was
observed in only one of four samples, and the
concentration in this sample was not signifi-
cantly different from background. Interestingly,
none of the 32 congeners were detected at levels
signiﬁcantly different from vehicle controls in
brain tissue from either males or females
exposed developmentally to A1254 at
0.1 mg/kg/day. In contrast, 12 congeners were
detected at levels signiﬁcantly increased relative
to vehicle controls in brains of both males and
females exposed developmentally to A1254 at
1 mg/kg/day. Detected congeners were pre-
dominantly ortho-substituted, and no signiﬁ-
cant differences were noted between sexes. 
Table 1. Physiologic variables during MCAO.
Females, A1254 treatment (mg/kg/day) Males, A1254 treatment (mg/kg/day)
Variable 0 0.1 1 0 0.1 1
MAP (mm Hg) 98 ± 4 86 ± 2* 87 ± 2* 111 ± 3 109 ± 3 99 ± 3*
Arterial blood pH 7.43 ± 0.01 7.42 ± 0.01 7.41 ± 0.01 7.46 ± 0.01 7.42 ± 0.02 7.43 ± 0.02
PaCO2 (mm Hg) 42 ± 2 44 ± 1 44 ± 3 41 ± 1 41 ± 2 44 ± 2 
PaO2 (mm Hg) 122 ± 4 131 ± 4 130 ± 8 122 ± 2 136 ± 6 119 ± 6
Rectal temperature (°C) 37.0 ± 0.1 37.1 ± 0.1 37.0 ± 0.1 37.0 ± 0.1 37.0 ± 0.1 37.0 ± 0.1
Head temperature (°C) 37.1 ± 0.1 36.9 ± 0.1 36.8 ± 0.1 37.2 ± 0.1 36.9 ± 0.1 36.9 ± 0.1
Blood glucose (g/dL) 128 ± 6 109 ± 5* 131 ± 7 124 ± 5 108 ± 3 130 ± 9
LDF  40 ± 2 39 ± 2 39 ± 2 41 ± 2 35 ± 2 37 ± 2
Abbreviations: LDF, laser Doppler ﬂowmetry; MAP, mean arterial blood pressure; PaCO2, arterial CO2 tension; PaO2, arterial
O2 tension. 
*p < 0.05 compared with vehicle treatment (ANOVA). 
Figure 2. Effects of A1254 treatments [0 (vehicle; n = 7), 0.1 (n = 7), or 1 mg/kg (n = 6) on maternal or fetal toxicity.
(A) Maternal body weight throughout gestation and lactation, (B) length of gestation, (C) litter size, (D) sex
ratio, (E) body weight of female offspring (n ≥ 11 per treatment group), and (F) body weight of male offspring
(n ≥ 11 per treatment group). See “Materials and Methods” for details. Data are presented as mean ± SE. 
*p < 0.05.
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*Effect of developmental A1254 exposure
on Bcl2 and Cyp2C11 expression in the
brain. Developmental A1254 exposure had no
effect on cortical or striatal levels of Bcl2
mRNA in either sex at PND7 (Figure 5 A,C).
In the PND50 brain, A1254 at 0.1 mg/kg/day
reduced Bcl2 expression in the female cortex
(Figure 5B), whereas both A1254 doses
increased Bcl2 in the male cortex (Figure 5D).
We next determined whether developmental
A1254 exposure increased Cyp2C11 mRNA
levels in the striatum of males or females at
PND7 or PND50. The only signiﬁcant effect
was decreased Cyp2C11 transcription in
PND50 females exposed developmentally to
either A1254 dose (Figure 6). 
Effect of developmental A1254 exposure
on sex hormone levels during MCAO. To test
the hypothesis that the neuroprotective effects
of developmental A1254 exposure against
cerebral ischemia are mediated by PCB effects
on estrogen levels, we quantiﬁed plasma levels
of estradiol and testosterone 22 hr after
MCAO. The only treatment-related effect
was a signiﬁcant increase in plasma estradiol
in females exposed developmentally to A1254
at 1 mg/kg/day; however, even these values
were low and physiologically unremarkable.
Discussion
In the present study, our data identify develop-
mental exposure to environmental contami-
nants as a novel determinant of adult
susceptibility to cerebral ischemia. Speciﬁcally,
we demonstrate that developmental exposure
to PCBs alters stroke outcome in adults,
although in an unexpected manner, given pre-
vious epidemiologic and laboratory evidence
suggesting that PCBs increase the incidence of
risk factors for stroke, such as diabetes (Everett
et al. 2007; Longnecker and Daniels 2001;
Vasiliu et al. 2006) and vascular disease
(Carpenter 2006; Hennig et al. 2005).
Paradoxically, we observed that developmental
PCB exposure provided protection against
ischemic injury, evident as decreased infarct
volume in adult male and female rats exposed
to A1254 at 1.0 or 0.1 mg/kg/day in the
maternal diet, respectively. Although these
PCB exposure levels are higher than current
background levels, they are about 3-fold lower
than those reported in children exposed prena-
tally to PCB-contaminated seafood (Grandjean
et al. 2001). Our congener-speciﬁc analyses of
brains from adult rats exposed developmentally
to A1254 at 1 mg/kg/day in the maternal diet
identiﬁed 12 predominantly ortho-substituted
congeners at concentrations ranging from
0.4 to 8.6 ng/g wet weight. Analyses of PCB
levels in human brains obtained from the gen-
eral adult population similarly identiﬁed pre-
dominantly ortho-substituted congeners at
concentrations ranging from 0.07 to 8.0 ng/g
wet weight (Chu et al. 2003; Covaci et al.
2002; Dewailly et al. 1999). Interestingly, our
analyses did not detect PCB congeners above
control levels in the brains of adult animals
exposed developmentally to A1254 at
0.1 mg/kg/day, even though this dose was
neuroprotective against focal cerebral ischemia
in females, suggesting that PCB effects on
stroke outcome may result from PCB inter-
actions with developmental processes. 
The mechanism(s) mediating the neuro-
protective effect of PCBs appear to be inde-
pendent of reported PCB effects on vascular
function. PCBs have been shown to interfere
with vascular function and induce microvessel
formation outside the brain (Eum et al. 2006;
Hennig et al. 2005; Tavolari et al. 2006), but
laser-Doppler ﬂowmetry (LDF) indicated that
cerebral blood ﬂow during MCAO was similar
between treatment groups. Although mean
arterial pressure (MAP) was within normal
physiologic parameters across all treatments,
we did observe a statistically significant
decrease in MAP among females in both the
low- and high-dose A1254 groups and among
males in the high-dose A1254 group.
However, it is unlikely that this contributes to
the neuroprotective effects of PCBs because
decreased MAP would be expected to worsen
PCBs alter stroke outcome
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Figure 4. Effects of A1254 exposure [0 (vehicle), 0.1, or 1 mg/kg] on CYP activity in the liver of adult rats; see
“Materials and Methods” for details. Activities of EROD (A) and PROD (B), biomarkers of exposure to
coplanar and noncoplanar PCBs, respectively, were measured in hepatic microsomes from adult female
(8–10 weeks of age) and male rats (6–8 weeks of age). Developmental PCB exposure caused a sex- and
dose-dependent increase in both EROD and PROD activity. Data are presented as mean ± SE; n = 8 per
treatment group per sex.
*p < 0.05. **p < 0.01. #p < 0.001. 
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Figure 3. Effects of A1254 exposure [0 (vehicle), 0.1, or 1 mg/kg] on infarct volume measured after 22 hr of
reperfusion following MCAO in female (8–10 weeks of age) and male rats (6–8 weeks of age); see
“Materials and Methods” for details. Representative photomicrographs of TTC-stained coronal slices
demonstrating infarcts (nonstained region) in the ipsilateral (left) cortex and striatum of females from vehi-
cle control (A) and 0.1-mg/kg/day (B) treatment groups. Infarct size was signiﬁcantly reduced in the striatum
of females (C) and males (D) in the 0.1- and 1.0-mg/kg A1254 groups, respectively. Data are presented as the
mean ± SE. n = 7–9 per treatment group. 
*p < 0.05. 
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Female Malecerebral blood ﬂow during MCAO, resulting in
larger infarcts. We also observed a statistically
signiﬁcant decrease in plasma glucose among
females in the 0.1-mg/kg/day A1254 dose
group. Although hypoglycemia has been
reported to induce ischemic tolerance in the
brain (Bergstedt et al. 1993), this effect was
observed only subsequent to severe insulin-
induced hypoglycemia. Because blood glucose
levels among females in the 0.1-mg/kg/day
A1254 group were still within normal physio-
logic range, it seems unlikely that this is the
mechanism by which PCBs confer protection
against focal cerebral ischemia. Thus, the pro-
tective effects of PCBs in ischemic brain injury
appear to be independent of PCB effects on
the vasculature and homeostatic regulation of
blood glucose, suggesting that although PCB
exposure may increase risk factors for stroke
incidence, such effects may be offset by PCB-
induced neuroprotection that decreases the
extent of damage caused by ischemic stroke. 
Stroke outcome can be signiﬁcantly altered
by preconditioning (Koerner and Alkayed
2007) induced by either mild cerebral ischemic
stress or exposure to noxious agents, including
the endotoxin lipopolysaccharide (Deplanque
and Bordet 2000), the oxidative phosphoryla-
tion inhibitor 3-nitropropionic acid (Nakase
et al. 2000; Sugino et al. 1999; Wiegand et al.
1999), and ethanol (Wang et al. 2007).
Mechanism(s) implicated in at least some types
of preconditioning include increased Bcl2 and
Cyp2C11 expression (Koerner and Alkayed
2007). We observed increased Bcl2 expression
in males at the protective developmental A1254
exposure (1.0 mg/kg/day), but it was also
increased at the nonprotective developmental
A1254 exposure (0.1 mg/kg/day), suggesting
that Bcl2 up-regulation alone does not mediate
the neuroprotective effects of developmental
PCB exposure. Moreover, Bcl2 expression was
reduced in females exposed to A1254 at the
neuroprotective dose of 0.1 mg/kg/day, sug-
gesting that Bcl2 up-regulation is not required
for PCB effects on infarct volume in these ani-
mals. Similarly, up-regulation of Cyp2C11
expression in the brain is unlikely to mediate
the neuroprotective effects of developmental
A1254 exposure since PCB-related effects on
Cyp2C11 expression did not correlate with
PCB-related decreases in infarct volume.
However, these data do not rule out the possi-
bility that PCBs confer protection against
ischemic injury by preconditioning, because
preconditioning can be elicited by mechanisms
other than Bcl2 and Cyp2C11 up-regulation,
including increased oxygen free radicals, cal-
cium inﬂux via N-methyl-D-aspartate (NMDA)
receptors, and proinflammatory cytokines
(Koerner and Alkayed 2007). How these signals
confer protection is not completely understood,
but working hypotheses include up-regulation
of endogenous antioxidant mechanisms in the
brain (Toyoda et al. 1997), such as superoxide
dismutase (Bordet et al. 2000; Kato et al. 1995;
Wada et al. 2001), and activation of transcrip-
tion factors implicated in neuroprotection,
Dziennis et al.
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Table 3. Estrogen and testosterone levels in plasma
22 hr after MCAO.
A1254 Estradiol Testosterone
(mg/kg/day) No. (pg/mL) (ng/mL)
Male
0 8 18 ± 1 2.14 ± 0.67
0.1 8 20 ± 2 2.91 ± 1.22
1 7 22 ± 3 2.97 ± 0.50
Female
0 8 18 ± 1 0.47 ± 0.06
0.1 8 24 ± 3 0.61 ± 0.05
1 9 27 ± 3* 0.51 ± 0.04
*p < 0.05 (ANOVA).
Table 2. Concentration of PCB congeners (ng/g wet weight) detected in brains of PND62 rats exposed
developmentally to A1254.
A1254 concentration (mg/kg/day)
PCB congener 0 (vehicle) 0.1 1
1 ortho substitution
PCB-105 BDL BDL 2.3  ± 0.4#
PCB-118 BDL BDL 6.3 ± 1.1#
PCB-156 BDL BDL 1.9 ± 0.2#
2 ortho substitutions
PCB-99 BDL BDL 7.8 ± 2.4**
PCB-128 BDL BDL 1.8 ± 0.4#
PCB-138 BDL 4.1 ± 2.0 8.6 ± 1.4**
PCB-153 1.20a  BDL 6.5 ± 1.0#
PCB-158 BDL BDL 1.8 ± 0.2#
PCB-170 BDL BDL 0.9 ± 0.2#
PCB-180 BDL BDL 1.4 ± 0.1#
3 ortho substitutions
PCB-183 BDL BDL 0.4 ± 0.1**
PCB-187 BDL BDL 1.0 ± 0.1#
BDL, below detection limit. n = 4 per treatment group. 
aConcentration detected in one of four samples; the other three samples were BDL. Other congeners that were tested and
found to be BDL in all samples include coplanar PCBs 37, 77, 126, and 169; mono-ortho-substituted PCBs 8, 28, 60, 66, 70, 74,
114, and 189; di-ortho-substituted PCBs 44, 49, 52, 82, 87, 101, and 166; and PCB179, which has four ortho substitutions. 
**p < 0.01. #p < 0.001 (ANOVA). 
Figure 5. Changes in levels of transcript encoding Bcl2 in rats after developmental exposure to A1254
(mg/kg/day). Total RNA was extracted from the cortex and striatum of females (A, B) and males (C, D) at
PND7 (A, C) and PND50 (B, D). Bcl2 mRNA was quantiﬁed by qRT-PCR and normalized against endogenous
18S RNA. Developmental A1254 exposure caused age-, dose- and sex-speciﬁc changes in cortical expres-
sion of Bcl2 mRNA independent of PCB-related changes in infarct volume. Data are presented as
mean ± SE; n = 5–6 per treatment group per sex. 
*p < 0.05. 
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Male (PND7) Male (PND50)such as cyclic AMP-response element binding
protein (CREB) (Hara et al. 2003; Tauskela
and Morley 2004) and nuclear factor-kappa B
(NF-κB) (Pradillo et al. 2005; Ravati et al.
2001). Interestingly, PCBs have been shown
to increase oxygen free radicals in cultured
neurons (Mariussen and Fonnum 2006),
enhance NMDA-mediated calcium influx
(Gafni et al. 2004), and increase levels of
proinflammatory cytokines in the brain
(Goodwill et al. 2007). Whether these alter-
nate mechanisms contribute to the neuro-
protective actions of developmental PCB
exposure against ischemic injury in the adult
brain remains to be determined.
Alternatively, or in addition, PCB effects
on infarct volume may be mediated by estro-
genic mechanisms. Estrogen protects both
male and female brains against ischemic dam-
age (McCullough et al. 2001; Rusa et al.
1999). Although we did not observe A1254-
induced changes in plasma concentrations of
either estradiol or testosterone in animals
undergoing MCAO, we cannot rule out the
possibility that A1254 altered estrogen signal-
ing via effects at the level of the estrogen
receptor. PCBs compete with estrogen for
binding to the estrogen receptor (Arcaro et al.
1999; DeCastro et al. 2006; Nesaretnam et al.
1996), and developmental PCB exposure has
recently been reported to increase estrogen
sensitivity (Ceccatelli et al. 2006) and to mod-
ulate sexual differentiation of the rodent brain
(Colciago et al. 2006; Weiss 2002) When
considered in the context of our observation
that neuroprotection was conferred in the
absence of detectable PCB levels in the female
brain at the time of MCAO and emerging evi-
dence that sex hormone effects on the develop-
ing brain may be important in establishing
differences in stroke outcome between the sexes
(Hurn et al. 2005), these observations suggest
the intriguing hypothesis that developmental
PCB exposure influences stroke outcome via
modulation of the sexual differentiation of the
developing brain. 
Whether modulation of estrogenic signal-
ing mediates the neuroprotective effects of
developmental PCB exposure remains to be
determined; however, such a mechanism sug-
gests an explanation for the different dose–
response relationship we observed between
males and females. If the estrogenic properties
of A1254 are additive with the protective
actions of endogenous estrogen, this might
explain why females are more sensitive to the
protective effects of developmental A1254
exposure. The protection conferred in females
was, however, lost at the higher developmental
A1254 exposure. It has previously been
reported that higher doses of estrogen are not
effective in reducing injury (Noppens et al.
2005; Rusa et al. 1999; Wilson et al. 2000).
Thus, exposure to A1254 at the higher dose
possibly increases estrogen activity in females to
an ineffective level, perhaps due to feedback
inhibition. Consistent with this possibility, in
males, which have lower levels of endogenous
estrogen, A1254 conferred protection only at
the higher exposure level. This seems a more
plausible mechanism than the one we consid-
ered experimentally, which was a difference in
PCB metabolism between sexes. Analyses of
CYP activity in liver microsomes revealed that
males in the vehicle control and 0.1-mg/kg/day
A1254 exposure groups had increased PROD
activity relative to females in comparable expo-
sure groups. Therefore, males may metabolize
noncoplanar PCBs more quickly than females,
suggesting that a higher dose of A1254 may be
required for an effect. However, congener-
speciﬁc analyses of PCBs in adult brains did not
reveal differences between sexes. Although it is
possible that we may have missed critical differ-
ences between the sexes in the developing brain
or in specific congeners not included in our
analytical proﬁle, these data suggest that differ-
ential PCB metabolism is not the principal
mechanism contributing to sex differences in
the dose–response relationship for developmental
A1254 exposure effects on stroke outcome. 
Conclusions
Our data demonstrate that developmental
A1254 exposure alters stroke outcome in the
adult brain. Although the mechanisms mediat-
ing this effect remain unclear, these findings
are important in that they establish develop-
mental exposures to environmental contami-
nants as potentially signiﬁcant determinants of
the adult brain’s response to ischemic injury.
These studies also identify developmental PCB
exposure as a unique experimental tool for
identifying novel therapeutic targets for limit-
ing neuronal damage following ischemic
injury. Determining which type(s) of PCBs
contribute to the observed effects will improve
assessments of PCB risks to human health, and
identifying cellular and molecular mechanisms
of PCB-induced neuroprotection will be neces-
sary for translating these novel findings into
potential stroke therapies. 
REFERENCES
Alkayed NJ, Murphy SJ, Traystman RJ, Hurn PD, Miller VM.
2000. Neuroprotective effects of female gonadal steroids
in reproductively senescent female rats. Stroke 31:61–168.
Arcaro KF, Yi L, Seegal RF, Vakharia DD, Yang Y, Spink DC,
et al. 1999. 2,2’,6,6’-Tetrachlorobiphenyl is estrogenic
in vitro and in vivo. J Cell Biochem 72:94–102.
Barlow BK, Cory-Slechta DA, Richfield EK, Thiruchelvam M.
2007. The gestational environment and Parkinson’s dis-
ease: evidence for neurodevelopmental origins of a neuro-
degenerative disorder. Reprod Toxicol 23:457–470.
Basha MR, Braddy NS, Zawia NH, Kodavanti PR. 2006.
Ontogenetic alterations in prototypical transcription factors
in the rat cerebellum and hippocampus following perinatal
exposure to a commercial PCB mixture. Neurotoxicology
27:118–124.
Bergstedt K, Hu BR, Wieloch T. 1993. Initiation of protein syn-
thesis and heat-shock protein-72 expression in the rat
brain following severe insulin-induced hypoglycemia. Acta
Neuropathol 86:145–153.
Bolin CM, Basha R, Cox D, Zawia NH, Maloney B, Lahiri DK, et al.
2006. Exposure to lead and the developmental origin of
oxidative DNA damage in the aging brain. FASEB J
20:788–790.
Bordet R, Deplanque D, Maboudou P, Puisieux F, Pu Q, Robin E,
et al. 2000. Increase in endogenous brain superoxide 
PCBs alter stroke outcome
Environmental Health Perspectives • VOLUME 116 | NUMBER 4 | April 2008 479
Figure 6. Correlation of PCB effects on Cyp2C11 mRNA levels and PCB effects on stroke outcome. Total
RNA was extracted from the striatum of females (A, B) and males (C, D) at PND7 (A, C) and PND50 (B, D).
Cyp2C11 mRNA was quantiﬁed by qRT-PCR and normalized against endogenous 18S RNA. Developmental
exposure to A1254 at 0.1 or 1.0 mg/kg/day in the maternal diet significantly decreased Cyp2C11 mRNA
expression in PND50 females (B), but had no effect on Cyp2C11 transcripts in the striatum of PND7 females
(A) or males of either age (C, D). Data are presented as mean ± SE; n = 5–6 per treatment group per sex.
*p < 0.05. #p < 0.001. 
1.5
1.0
0.5
0.0
R
a
t
i
o
 
o
f
 
2
C
1
1
/
1
8
S
 
R
N
A A B
0
C D
A1254 (mg/kg/day)
0.1 1
4
3
2
1
0
0 0.1 1
A1254 (mg/kg/day)
R
a
t
i
o
 
o
f
 
2
C
1
1
/
1
8
S
 
R
N
A
*
#
A1254 (mg/kg/day) A1254 (mg/kg/day)
0 0.1 1 0 0.1 1
20
15
10
5
0
R
a
t
i
o
 
o
f
 
2
C
1
1
/
1
8
S
 
R
N
A
2.0
1.5
1.0
0.5
0.0
R
a
t
i
o
 
o
f
 
2
C
1
1
/
1
8
S
 
R
N
A
Female (PND7) Female (PND50)
Male (PND7) Male (PND50)
0
0.1
1Dziennis et al.
480 VOLUME 116 | NUMBER 4 | April 2008 • Environmental Health Perspectives
dismutase as a potential mechanism of lipopolysaccharide-
induced brain ischemic tolerance. J Cereb Blood Flow
Metab 20:1190–1196.
Carpenter DO. 2006. Polychlorinated biphenyls (PCBs): routes
of exposure and effects on human health. Rev Environ
Health 21:1–23.
Ceccatelli R, Faass O, Schlumpf M, Lichtensteiger W. 2006.
Gene expression and estrogen sensitivity in rat uterus
after developmental exposure to the polybrominated
diphenylether PBDE 99 and PCB. Toxicology 220:104–116.
Chen YC, Guo YL, Hsu CC, Rogan WJ. 1992. Cognitive develop-
ment of Yu-Cheng (“oil disease”) children prenatally
exposed to heat-degraded PCBs. JAMA 268:3213–3218.
Cheng J, Alkayed NJ, Hurn PD. 2007. Deleterious effects of
dihydrotestosterone on cerebral ischemic injury. J Cereb
Blood Flow Metab 27:1553–1562.
Chu S, Covaci A, Schepens P. 2003. Levels and chiral signatures
of persistent organochlorine pollutants in human tissues
from Belgium. Environ Res 93:167–176.
Colciago A, Negri-Cesi P, Pravettoni A, Mornati O, Casati L,
Celotti F. 2006. Prenatal Aroclor 1254 exposure and brain
sexual differentiation: effect on the expression of testos-
terone metabolizing enzymes and androgen receptors in
the hypothalamus of male and female rats. Reprod Toxicol
22:738–745.
Covaci A, de Boer J, Ryan JJ, Voorspoels S, Schepens P. 2002.
Distribution of organobrominated and organochlorinated
contaminants in Belgian human adipose tissue. Environ Res
88:210–218.
Craft TK, Zhang N, Glasper ER, Hurn PD, Devries AC. 2006.
Neonatal factors influence adult stroke outcome.
Psychoneuroendocrinology 31:601–613.
DeCaprio AP, Johnson GW, Tarbell AM, Carpenter DO,
Chiarenzelli JR, Morse GS, et al. 2005. Polychlorinated
biphenyl (PCB) exposure assessment by multivariate statis-
tical analysis of serum congener proﬁles in an adult Native
American population. Environ Res 98:284–302.
DeCastro BR, Korrick SA, Spengler JD, Soto AM. 2006.
Estrogenic activity of polychlorinated biphenyls present in
human tissue and the environment. Environ Sci Technol
40:2819–2825.
Deplanque D, Bordet R. 2000. Pharmacological preconditioning
with lipopolysaccharide in the brain. Stroke 31:1465–1466.
Dettmers C, Hartmann A, Rommel T, Kramer S, Pappata S,
Young A, et al. 1994. Immersion and perfusion staining
with 2,3,5-triphenyltetrazolium chloride (TTC) compared to
mitochondrial enzymes 6 hours after MCA-occlusion in
primates. Neurol Res 16:205–208.
Dewailly É, Mulvad G, Pedersen HS, Ayotte P, Demers A,
Weber JP, et al. 1999. Concentration of organochlorines in
human brain, liver, and adipose tissue autopsy samples
from Greenland. Environ Health Perspect 107:823–828. 
Eum SY, Rha GB, Hennig B, Toborek M. 2006. c-Src is the pri-
mary signaling mediator of polychlorinated biphenyl-
induced interleukin-8 expression in a human microvascular
endothelial cell line. Toxicol Sci 92:311–320.
Everett CJ, Frithsen IL, Diaz VA, Koopman RJ, Simpson WM Jr,
Mainous AG III. 2007. Association of a polychlorinated
dibenzo-p-dioxin, a polychlorinated biphenyl, and DDT
with diabetes in the 1999-2002 National Health and
Nutrition Examination Survey. Environ Res 103:413–418.
Gafni J, Wong PW, Pessah IN. 2004. Non-coplanar 2,2’,3,5’,6-
pentachlorobiphenyl (PCB 95) amplifies ionotropic gluta-
mate receptor signaling in embryonic cerebellar granule
neurons by a mechanism involving ryanodine receptors.
Toxicol Sci 77:72–82.
GenBank. 2007. GenBank Overview. Available: http://www.
ncbi.nlm.nih.gov/Genbank/ [accessed 25 February 2008]. 
Goodwill MH, Lawrence DA, Seegal RF. 2007. Polychlorinated
biphenyls induce proinflammatory cytokine release and
dopaminergic dysfunction: protection in interleukin-6
knockout mice. J Neuroimmunol 183:125–132.
Grandjean P, Weihe P, Burse VW, Needham LL, Storr-Hansen E,
Heinzow B, et al. 2001. Neurobehavioral deﬁcits associated
with PCB in 7-year-old children prenatally exposed to
seafood neurotoxicants. Neurotoxicol Teratol 23:305–317.
Hara T, Hamada J, Yano S, Morioka M, Kai Y, Ushio Y. 2003.
CREB is required for acquisition of ischemic tolerance in
gerbil hippocampal CA1 region. J Neurochem 86:805–814.
Hatfield RH, Mendelow AD, Perry RH, Alvarez LM, Modha P.
1991. Triphenyltetrazolium chloride (TTC) as a marker for
ischaemic changes in rat brain following permanent middle
cerebral artery occlusion. Neuropath Appl Neurobiol
17:61–67.
Hennig B, Reiterer G, Majkova Z, Oesterling E, Meerarani P,
Toborek M. 2005. Modiﬁcation of environmental toxicity by
nutrients: implications in atherosclerosis. Cardiovasc
Toxicol 5:153–160.
Hsu PC, Pan MH, Li LA, Chen CJ, Tsai SS, Guo YL. 2007. Exposure
in utero to 2,2’,3,3’,4,6’-hexachlorobiphenyl (PCB 132)
impairs sperm function and alters testicular apoptosis-
related gene expression in rat offspring. Toxicol Appl
Pharmacol 221:68–75.
Hurn PD, Vannucci SJ, Hagberg H. 2005. Adult or perinatal
brain injury: does sex matter? Stroke 36:193–195.
Jursa S, Chovancova J, Petrik J, Loksa J. 2006. Dioxin-like and
non-dioxin-like PCBs in human serum of Slovak population.
Chemosphere 64:686–691.
Kato H, Kogure K, Araki T, Liu XH, Kato K, Itoyama Y. 1995.
Immunohistochemical localization of superoxide dismutase
in the hippocampus following ischemia in a gerbil model of
ischemic tolerance. J Cereb Blood Flow Metab 15:60–70.
Kennedy SW, Jones SP. 1994. Simultaneous measurement of
cytochrome P4501A catalytic activity and total protein
concentration with a fluorescence plate reader. Anal
Biochem 222:217–223.
Kitagawa K. 2007. CREB and cAMP response element-mediated
gene expression in the ischemic brain. FEBS J 274:3210–3217.
Koerner IP, Alkayed NJ. 2007. Ischemic preconditioning. In:
Acute Stroke: Bench to Bedside (Bhardwaj A, Alkayed NJ,
Kirsch JR, Traystman RJ, eds). Neurological Disease and
Therapy Series, Vol 88. New York:Informa Health Care
USA, Inc., 432–438.
Kono H, Bradford BU, Yin M, Sulik KK, Koop DR, Peters JM,
et al. 1999. CYP2E1 is not involved in early alcohol-induced
liver injury. Am J Physiol 277: G1259–1267.
Kostyniak PJ, Hansen LG, Widholm JJ, Fitzpatrick RD, Olson JR,
Helferich JL, et al. 2005. Formulation and characterization
of an experimental PCB mixture designed to mimic human
exposure from contaminated ﬁsh. Toxicol Sci 88:400–411.
Kramer HJ, Drenth H, Fleuren R, Hengeveld S, Seinen W,
VandenBerg M. 1999. Metabolic rate constants of Ugilec
141 isomers and polychlorinated biphenyl congeners using
rat hepatic microsomes and the identification of involved
cytochrome P450 enzymes. Organohalogen Compounds
2:185–189.
Longnecker MP, Daniels JL. 2001. Environmental contaminants
as etiologic factors for diabetes. Environ Health Perspect
109(suppl 6):871–876.
Lubet RA, Guengerich FP, Nims RW. 1990. The induction of
alkoxyresorufin metabolism: a potential indicator of envi-
ronmental contamination. Arch Environ Contamin Toxicol
19:157–163.
Mariussen E, Fonnum F. 2006. Neurochemical targets and
behavioral effects of organohalogen compounds: an
update. Crit Rev Toxicol 36:253–289.
Mattson MP. 2007. Calcium and neurodegeneration. Aging Cell
6:337–350.
McCullough LD, Alkayed NJ, Traystman RJ, Williams MJ,
Hurn PD. 2001. Postischemic estrogen reduces hypo-
perfusion and secondary ischemia after experimental
stroke. Stroke 32:796–802.
McMillen IC, Robinson JS. 2005. Developmental origins of the
metabolic syndrome: prediction, plasticity, and program-
ming. Physiol Rev 85:571–633.
Meerts IA, Hoving S, van den Berg JH, Weijers BM, Swarts HJ,
van der Beek EM et al. 2004. Effects of in utero exposure
to 4-hydroxy-2,3,3’,4’,5-pentachlorobiphenyl (4-OH-CB107)
on developmental landmarks, steroid hormone levels, and
female estrous cyclicity in rats. Toxicol Sci 82:259–267.
Morley R. 2006. Fetal origins of adult disease. Sem Fetal
Neonat Med 11:73–78.
Nakase H, Heimann A, Uranishi R, Riepe MW, Kempski O. 2000.
Early-onset tolerance in rat global cerebral ischemia induced
by a mitochondrial inhibitor. Neurosci Lett 290:105–108.
Nesaretnam K, Corcoran D, Dils RR, Darbre P. 1996. 3,4,3’,4’-Tetra-
chlorobiphenyl acts as an estrogen in vitro and in vivo. Mol
Endocrinol 10:923–936.
Noppens RR, Kofler J, Hurn PD, Traystman RJ. 2005. Dose-
dependent neuroprotection by 17beta-estradiol after
cardiac arrest and cardiopulmonary resuscitation. Crit
Care Med 33:1595–1602.
Okuno S, Nakase H, Sakaki T. 2001. Comparative study of 2,3,5-
triphenyltetrazolium chloride (TTC) and hematoxylin-eosin
staining for quantiﬁcation of early brain ischemic injury in
cats. Neurol Res 23:657–661.
Paxinos G, Watson C. 1986. The Rat Brain in Stereotaxic
Coordinates. 2nd ed. New York: Academic Press. 
Pradillo JM, Romera C, Hurtado O, Cardenas A, Moro MA,
Leza JC, et al. 2005. TNFR1 upregulation mediates toler-
ance after brain ischemic preconditioning. J Cereb Blood
Flow Metab 25:193–203.
Ravati A, Ahlemeyer B, Becker A, Klumpp S, Krieglstein J. 2001.
Preconditioning-induced neuroprotection is mediated by
reactive oxygen species and activation of the transcription
factor nuclear factor-kappaB. J Neurochem 78:909–919.
Rusa R, Alkayed NJ, Crain BJ, Traystman RJ, Kimes AS,
London ED, et al. 1999. 17beta-estradiol reduces stroke injury
in estrogen-deﬁcient female animals. Stroke 30:1665–1670.
Schantz SL, Widholm JJ, Rice DC. 2003. Effects of PCB expo-
sure on neuropsychological function in children. Environ
Health Perspect 111:357–576.
Sethajintanin D, Anderson KA. 2006. Temporal bioavailability of
organochlorine pesticides and PCBs. Environ Sci Technol
40:3689–3695.
Sethajintanin D, Johnson ER, Loper BR, Anderson KA. 2004.
Bioaccumulation proﬁles of chemical contaminants in ﬁsh
from the lower Willamette River, Portland Harbor, Oregon.
Arch Envrion Contam Toxicol 46:114–123.
Shcherbatykh I, Huang X, Lessner L, Carpenter DO. 2005.
Hazardous waste sites and stroke in New York State.
Environ Health 4:18; doi:10.1186/1476-069X-4-18 [Online
29 August 2005]. 
Stewart P, Darvill T, Lonky E, Reihman J, Pagano J, Bush B.
1999. Assessment of prenatal exposure to PCBs from
maternal consumption of Great Lakes fish: an analysis of
PCB pattern and concentration. Environ Res 80:S87–S96.
Sugino T, Nozaki K, Takagi Y, Hashimoto N. 1999. 3-Nitropropionic
acid induces ischemic tolerance in gerbil hippocampus
in vivo. Neurosci Lett 259:9–12.
Tauskela JS, Morley P. 2004. On the role of Ca2+ in cerebral
ischemic preconditioning. Cell Calcium 36:313–322.
Tavolari S, Bucci L, Tomasi V, Guarnieri T. 2006. Selected poly-
chlorobiphenyls congeners bind to estrogen receptor
alpha in human umbilical vascular endothelial (HUVE)
cells modulating angiogenesis. Toxicology 218:67–74.
Toyoda T, Kassell NF, Lee KS. 1997. Induction of ischemic toler-
ance and antioxidant activity by brief focal ischemia.
Neuroreport 8:847–851.
Tureyen K, Vemuganti R, Sailor KA, Dempsey RJ. 2004. Infarct
volume quantiﬁcation in mouse focal cerebral ischemia: a
comparison of triphenyltetrazolium chloride and cresyl vio-
let staining techniques. J Neurosci Methods 139:203–207.
Vasiliu O, Cameron L, Gardiner J, Deguire P, Karmaus W. 2006.
Polybrominated biphenyls, polychlorinated biphenyls, body
weight, and incidence of adult-onset diabetes mellitus.
Epidemiology 17:352–359.
Wada K, Miyazawa T, Nomura N, Tsuzuki N, Nawashiro H,
Shima K. 2001. Preferential conditions for and possible
mechanisms of induction of ischemic tolerance by
repeated hyperbaric oxygenation in gerbil hippocampus.
Neurosurgery 49:160–166.
Wang Q, Sun AY, Simonyi A, Kalogeris TJ, Miller DK, Sun GY,
et al. 2007. Ethanol preconditioning protects against
ischemia/reperfusion-induced brain damage: role of
NADPH oxidase-derived ROS. Free Radic Biol Med
43:1048–1060.
Weiss B. 2002. Sexually dimorphic nonreproductive behaviors
as indicators of endocrine disruption. Environ Health
Perspect 110(suppl 3):387–391.
Wiegand F, Liao W, Busch C, Castell S, Knapp F, Lindauer U,
et al. 1999. Respiratory chain inhibition induces tolerance
to focal cerebral ischemia. J Cereb Blood Flow Metab
19:1229–1237.
Wilson ME, Dubal DB, Wise PM. 2000. Estradiol protects against
injury-induced cell death in cortical explant cultures: a role
for estrogen receptors. Brain Res 873:235–242.
Zawia NH, Basha MR. 2005. Environmental risk factors and the
developmental basis for Alzheimer’s disease. Rev Neurosci
16:325–337.